The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated ...
Chief Scientific Officer Pedro Beltran will succeed Eli Wallace as CEO of BridgeBio Oncology Therapeutics, as the board eyes a busy period of clinical advancement in the RAS oncology space.
RAS genes constitute the most regularly mutated oncogene family in cancer. Indeed, RAS genes constituted the most regularly mutated oncogenes in the top three causes of cancer deaths in the US in 2016 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results